Catabasis begins Phase I/II trial of CAT-1004 to treat duchenne muscular dystrophy
CAT-1004 is an oral small-molecule that the Company believes has the potential to be a disease-modifying therapy for DMD patients, regardless of the underlying dystrophin mutation, by inhibiting
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.